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A B S T R A C T
Purpose: To study the antiepileptic drug treatment of children at a referral centre for epilepsy, including a
follow-up study three months after discharge.
Material and methods: The study includes children admitted to The National Centre for Epilepsy in
Norway. Datawere collected from themedical records of 261 children, and a questionnaire regarding the
pharmacological treatment was sent to their parents three months after discharge.
Results: The most common reasons for admission to the referral centre were medical and diagnostic
evaluation. New antiepileptic drugs were used more frequently than old, in 251 and 158 cases,
respectively. 53 and 54% were using polytherapy at admission and discharge, respectively.
Levetiracetam, valproate and lamotrigine were the most frequently used antiepileptic drugs before,
during, and after the stay at the centre. Levetiracetam was the only drug being more frequently used at
discharge/three months after discharge than at admission. Dosage adjustments were made in 83% of the
patients following measurement of serum concentrations and clinical evaluation.
According to the parents the number of adverse effects had been reduced by 20% three months after
discharge. Likewise 40% stated that their children experienced better seizure control, and 47% that their
family experienced a better everyday life after the stay.
Conclusion: Close comprehensive follow-up of children admitted to the referral centre, with main focus
on optimalization of the pharmacological treatment, is of importance regarding quality of life aspects
both to the children and their families.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The National Centre for Epilepsy in Norway is a referral centre
admitting patients with refractory epilepsy from the whole
country. Most of the patients have used various antiepileptic
drugs (AEDs) and drug combinations without achieving satisfac-
tory seizure control. There are four wards for adolescents/adults,
four wards for children aged 0–16 years, a neurodiagnostic
department, a nursery school and a school for children 6–16
years of age at the premises; the goal being to offer comprehensive
care to the patients.* Corresponding author at: National Centre for Epilepsy, Division of Clinical
Neuroscience, Rikshospitalet, P.O. Box 53, N-1306 Bærum postterminal, Norway.
Tel.: +47 67 50 10 00; fax: +47 67 54 04 96.
E-mail addresses: elisif.rytter@epilepsy.no (E. Rytter),
cecilie.landmark@hf.hio.no (C.J. Landmark), svein.johannessen@epilepsy.no
(S.I. Johannessen).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.05.011The term comprehensive care implies to offer integrated
multidisciplinary services, including physical, social, and voca-
tional habilitation and rehabilitation, and if required, patients
may attend school.1 About 30% of patients with epilepsy will
be in need of comprehensive care at a referral centre where
they can stay for a longer time than in ordinary hospital wards.
The specialists in paediatrics or neurology who establish the
diagnosis of epilepsy and initiate drug therapy should cooperate
closely with the local general practitioner, nurse, social worker,
school teachers and psychologist if necessary.1 The situation
for many of these children with epilepsy is complicated, and
the follow-up of many of the individual patients is often
difﬁcult.
The purpose of the present study was to investigate the
characteristics of children admitted to a referral centre for
epilepsy, and the use of AEDs in these children, as studied by
data from themedical records.We also wanted to study the impact
of the stay, where focus is on optimalized pharmacological
treatment, along with integrated multidisciplinary services, asvier Ltd. All rights reserved.
Table 1
Demographic data and characteristics of the patient populationa.
Patient characteristics Number
Age 8.3 years (0–16)
0–3 years 30
4–7 years 80
8–11 years 94
12–16 years 57
Duration of stay (days) 8.4 (1–35)
Ward A (children 0–10 years) 16.2 (2-30)
Ward B (short-stay ward 0–16 years) 3.1 (1–28)
Ward C (epilepsy and learning disabilitiy 0–16 years) 9.0 (1–22)
Ward D (10–16 years) 17.0 (1–35)
a Age and duration of stay are shown as mean values with range in parenthesis
(n = 261).
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discharged from the centre.
2. Materials and methods
The study comprised children admitted to the National
Centre for Epilepsy from August to December 2006. Children
discharged with at least one AED were included in the study. If
the child was admitted more than once during the period, only
data from the last admission were recorded. Demographic and
clinical data were collected from medical records at the centre,
including year of birth, gender, reason for admission, seizure
types and data regarding the use of AEDs. The registered
epilepsy diagnoses and seizure types in the medical records
were grouped based on the International classiﬁcation system
ICD-10: focal epilepsies included the diagnosis categories G40.0,
G40.1 and G40.2 and generalized/multifocal epilepsies G40.3
and G40.4. G40.8 consisted of epilepsy and epileptic syndromes
undetermined as to whether they were focal or generalized,
mostly sleep-induced epilepsy, but also including Landau–
Kleffner syndrome (LKS), epilepsy with continuous spike wave
during sleep (CSWS), and unspeciﬁed epilepsies included G40.6,
G40.7, G40.9 and other.2
A questionnaire was sent to the parents three months after
discharge. Two hundred and sixty one children, 153 boys and
108 girls were included. In the questionnaire the parents
answered both closed and open questions; ﬁrst what medication
the child currently was using and whether that medication was
the same as at discharge from the centre. Then, whether the
seizure situation was better, worse or unchanged, and in more
detail the number of seizures each day or week and how long
they lasted, before and after admission to the centre, according
to the patients’ seizure diaries. There were also questions
regarding adverse effects before and after admission, and lastly,
they were asked whether they found everyday life better, worse
or unchanged after the stay at the centre. A reminder was sentTable 2
Characteristics of patients with various epilepsy categoriesa.
Focal Generali
ICD-10 diagnosis code G.40.0, G.40.1, G.40.2 G.40.3, G
Number of patients 87 79
Mean age (range) 12 (2–15) 7 (1–14)
Most common reason for admission (number) Medical
evaluation (40)
Medical
evaluatio
New (old) AEDs in use within each category 92 (58) 74 (54)
Number of patients with comorbid conditions 61 60
CSWS, epilepsy with continuous spike wave during sleep and LKS, Landau–Kleffner sy
uncertain about the epilepsy diagnosis, not deﬁned epilepsy.
a Age is shown as mean values with range in parenthesis (n = 261).once to those who did not reply at the ﬁrst receipt. 157 of the
261 questionnaires (60%) were answered and returned. All data
were anonymized, by giving each form a number. The study was
approved by the local ethical committee, as a part of the quality
assurance at the centre.
3. Results
3.1. Patient population
Patient characteristics are shown in Tables 1 and 2. The mean
number of days at the centre was not inﬂuenced by the seizure
type (9–10 days for patients in all four groups of epilepsies).
Mainly due to the short-stay ward, but also at the other wards,
children were frequently re-admitted. The hospital policy is to
offer frequent stays to the patients rather than one prolonged stay.
In 2006 there were 549 admissions of children, of those 223 were
re-admissions.
The youngest children more often had generalized/multifocal
or unspeciﬁed epilepsies while the oldest children most often
had focal epilepsies (Table 2). The majority of the children were
admitted due to unsatisfactory seizure control and for drug
adjustments, including both change of drug and/or change of
dose (48%). Other reasons for admission included diagnostic
evaluation (36%), in most cases with EEG-monitoring (standard,
ambulatory, or long-term video-EEG) and post-surgical evalua-
tion (13%). Eight percent were admitted for a psychological and
pedagogical elucidation, seven percent for evaluation for
possible epilepsy surgery or vagal nerve stimulation, and 12%
for other reasons (including ketogenic diet, follow-up of vagal
nerve stimulation and steroid treatment). The most common
reasons for admission according to the various seizure types are
given in Table 2.
3.2. Clinical use of antiepileptic drugs
3.2.1. New vs. old AEDs
Comparison was made between AEDs used by the children at
admission, at discharge and three months after discharge, based
on data from the medical records and the answers from the
questionnaire (Fig. 1). Levetiracetam, valproate and lamotrigine
were the most frequently used AEDs, before, during and after the
stay at the centre. Levetiracetam was the only drug being more
frequently used at discharge/three months after discharge than
at admission. Levetiracetam was predominantly used in epilepsy
and epileptic syndromes undetermined as to whether they were
focal or generalized such as sleep-induced epilepsy (the
majority), LKS and epilepsy with CSWS (76% of the patients).
Levetiracetam was used in about 30% of patients with focal and
generalized/multifocal epilepsies and in 14% with unspeciﬁed
epilepsies at discharge (Fig. 2). Both valproate and lamotrigine
were used in all epilepsy types, but most often in focal andzed/multifocal Sleep-induced epilepsy, CSWS, LKS Unspeciﬁed
.40.4 G.40.8 G.40.6, G.40.7, G.40.9
67 28
9 (3–13) 7 (1–13)
n (40)
Diagnosis
evaluation (34)
Medical and diagnosis
evaluation (9, 9)
69 (26) 16 (20)
39 17
ndrome. Unspeciﬁed epilepsies include the patients with undetermined epilepsy,
Fig. 1. Use of AEDs at admission, discharge and three months after discharge from
the epilepsy centre based on data from the medical journal and answers from the
questionnaire (n = 157).
Fig. 2. Use of AEDs for different seizure types at discharge from the epilepsy centre
(n = 261). CSWS, epilepsy with continuous spike wave during sleep and LKS,
Landau–Kleffner syndrome.
Fig. 3. Use of AEDs in different age groups at discharge from the epilepsy centre
(n = 261).
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oxcarbazepine was predominantly used in focal epilepsies, and
zonisamide was mostly used in generalized/multifocal epilep-
sies. Less than 10 patients used sulthiame, vigabatrin, phenytoin
and acetazolamide, and no patients used ethosuximide and
phenobarbital at discharge. Based on the data presented in Fig. 2,
new AEDs were used much more frequently than older AEDs,
totally 251 and 158 times, respectively. It was noted that most
patients used more than one AED (see Section 3.2.4). New AEDs
are deﬁned as drugs marketed after 1990 and include lamo-trigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin and
zonisamide. According to the various seizure types, new AEDs
were preferred in all seizure types except unspeciﬁed (Table 2).
There were no differences in the type of AEDs used at discharge
between the children whose parents answered the questionnaire
and the total population (data not shown).
3.2.2. Age
Fig. 3 shows the most frequently used AEDs in different age
groups at discharge from the centre (n = 261). Levetiracetam was
used less frequently in the younger age groups (13%) compared to
in the older age groups (40%). Valproate was used in 50% of the
youngest children compared to 30% in the groups from 4 to 11
years old and only in 15% in the oldest age group (12–16 years old).
Lamotrigine was used in 13% of the youngest children, in 24% from
4 to 7 years old and in 30% of the children from 8 to 16 years old.
Clonazepam was frequently used in the youngest children (30%),
less than 10% in the older children and not at all in the oldest
children. Topiramate was used in 27% of the youngest children and
less frequently in the older age groups (7–15%). The use of
oxcarbazepine and carbamazepine was minor in the three
youngest age groups, but was used in 10% and 20% of the oldest
children, respectively.
Based on the results presented in Fig. 3, the youngest children
used older AEDs more frequently than newer AEDs, in 37 and 21
cases, respectively. In children 4–7 and 8–11 years old, new AEDs
were used most frequently, 69 and 89 times, respectively, while
older drugs were used 61 and 59 times, respectively. In the oldest
children, new AEDs were used predominantly, 52 times compared
to 29 times. Note that many of the children used more than one
AED.
3.2.3. TDM
Therapeutic drug monitoring (TDM) is implemented for the
follow-up of the pharmacological treatment of all patients at the
centre. The mean serum concentrations compared to the reference
ranges for the various drugs are shown in Table 3. The mean
concentrations are below the reference range for zonisamide and
clonazepam, while they are in the middle for carbamazepine and
valproate. For the other AEDs the mean serum concentrations are
low, but within the reference ranges.
Of the 261 patients, 31 patients started with a new AED, 26
patients stopped using one or two AEDs, and 16 patients switched
Table 3
Serum concentrations of AEDs in relation to reference ranges for childrena.
AED Serum concentrations
(mmol/l)
Number of
children
Reference
range
(mmol/l)b
Carbamazepine 31 (10–43) 15 15–45
Clobazam 0.92 (0.37–1.43) 4 0.1–1
Clonazepam 59 (28–106) nmol 7 60–220 nmol
Lamotrigine 16 (4–38) 46 10–35
Levetiracetam 42 (10–112) 64 35–120
Oxcarbazepine 72 (31–111) 13 50–140
Phenytoin 48 (23–84) 4 40–80
Topiramate 18 (11–27) 21 15–60
Valproate 451 (141–688) 55 300–600
Zonisamide 39 (10–105) 8 45–180
a The mean serum concentrations are given with range in parenthesis (n = 237).
The serum concentrations for nitrazepam were not obtained, and the AEDs
measured in less than 4 children are not presented (acetazolamide, ethosuximide,
sulthiame, vigabatrin).
b 14–16.
Fig. 4. The ten most frequently reported adverse effects before and after the stay at
the epilepsy centre (n = 157).
E. Rytter et al. / Seizure 18 (2009) 573–579576from one AED to another. Levetiracetam treatment was initiated in
17 patients. In 10 cases the treatment was added to the AEDs the
children were already using, and in seven of them it was switched
from valproate, lamotrigine or clobazam. Extensive dosage
adjustments were carried out during the stay, including dosage
titration during initiation and withdrawal of a drug. For the new
AEDs levetiracetam, topiramate, oxcarbazepine and zonisamide,
the dosages were increased to a much larger extent than the
number of reductions, while valproate and clonazepam dosages
were predominantly reduced. In total, dosage adjustments were
made 189 times in 130 of 157 patients (83%) – from one to four
adjustments in one patient – following measurement of serum
concentrations and clinical consideration. In addition, further
recommendations for dosage adjustments after discharge were
made in 52 cases.
3.2.4. Polytherapy
Themajority of the patients were using one or two AEDs both at
admission and at discharge: the medical records showed that 114
and 120 children used one AED at admission and discharge,
respectively, while 101 and 104 children used two AEDs,
respectively. Thirty-two patients were using three AEDs both at
admission and at discharge, while six were using four at admission
and ﬁve at discharge. At admission, eight children did not use any
AEDs, but all children were discharged with at least one AED (as
that was one of the inclusion criteria). Two hundred and nine
children (80%) used the same number of AEDs at admission
compared to at discharge, 30 children used more AEDs (12%) and
22 children used less AEDs (8%) at discharge from the centre. There
were 14 different AEDs in use, as shown in Figs. 2 and 3. Therewere
more parents of children who used polytherapy that did not return
the questionnaire (63% vs. 54%).
3.2.5. Adverse effects
The parents were asked about adverse effects thought to be due
to AEDs before admission to the centre, and three months after
discharge. These questions were open, and 54 different adverse
effects were reported. They were grouped into categories, and the
ten most frequently reported adverse effects before and after
admission are listed in Fig. 4, where behavioural changes,
somnolence and drowsiness were reported most frequently. There
was a tendency that the more serious adverse effects affecting
cognition were less pronounced after discharge. The number of
adverse effects was reduced by 20%; 47% and 37% of the patients
experienced side effects before and after the stay at the centre,
respectively.3.3. Seizure control and everyday life
According to the questionnaires, twenty-three patients
(15%) became seizure free after the stay at the centre. The
group of patients with several seizures every day was reduced
by 25%, from 56 to 43 patients. Forty-three patients (27%) had
fewer/less serious seizures after the stay. Reduction in seizure
frequency or seizure freedom was independent of epilepsy
diagnosis.
According to the parents’ subjective view and their seizure
diaries, 40% of the children experienced a better seizure situation
regarding duration and severity of seizures, and 47% of the families
experienced a better everyday life after the stay at the centre. 12
patients experienced aggravation of seizures, and seven a
worsening of everyday life. The use of AEDs, i.e. practical
considerations and compliance, was unchanged in a majority of
the cases.
3.4. Comorbid conditions and concomitant medication
Two-thirds of the children (177 out of 261) suffered from
comorbid conditions; they had 1–5 other diagnosis than
epilepsy. Of these patients, 47% had one comorbid condition,
36% had two and 17% had three or more comorbid conditions.
The most commonly occurring comorbid conditions were
developmental disorders (15%) and attention deﬁcit hyperac-
tivity disorder (ADHD) (10%) (Table 4). According to the
various epilepsy types, 76% of patients with generalized/multi-
focal epilepsy suffered from comorbid conditions, 70% of the
patients with focal epilepsy, and 58 and 60% of the patients
with epilepsies undetermined as to whether they were
focal or generalized, and unspeciﬁed epilepsies, respectively
(Table 2).
One-third of the patients were also taking other drugs in
addition to AEDs; hypnotics/sedatives including melatonin,
centrally acting sympathomimetics, drugs for obstructive air-
way diseases or antihistamines (Table 4). Laxatives, drugs for
gastro-oesophageal reﬂux and dietary supplements were used
by less than 10%. Other medications used by four or fewer
children were antibiotics, desmopressin, cortisone, levothyrox-
ine, analgesics, antimigraine preparations, antipsychotics and
diuretics.
Table 4
The most commonly occurring comorbid conditions among the children and
relevant medication (n = 261).
Comorbid conditions Relevant medication
CNS related Sedatives, melatonin (40)
Delayed development, mentally
and/or motor (55)
Attention deﬁcit hyperactivity
disorder (ADHD) (26)
Centrally acting sympatomimetics (31)
Cerebral palsy (18)
Tuberous sclerosis (8)
Dyslexia (10)
Other
Asthma, allergy (16) Corticosteroids, b2-agonists,
antihistamines (31)
Gastro-oesophageal reﬂux (10) Proton pump inhibitors, H2-antagonists,
laxatives, dietary supplements (24)
The number of patients is given in parenthesis.
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4.1. Clinical use of AEDs
The results demonstrated that there was no difference in the
total use of the various AEDs after admission to the centre, but
dosage adjustments weremade in themajority of the patients, and
this includes also the patients whowere titrated up and downwith
two AEDs for a period during a change of the medication. The
reasons for admission also show that the pharmacological
treatment is in focus, as half of the patients were admitted to
the centre for changes in their medication.
4.1.1. New vs. old AEDs
Levetiracetamwas themost commonly used AEDbefore, during
and after the stay at the centre, and it was the only drug more
frequently used after discharge than at admission. Levetiracetam
was marketed in 2001 and is the most commonly used newer AED
at the centre at large. This differs from the country as a whole, as
lamotrigine was the most commonly used AED in 2006 and
carbamazepine the most commonly used AED from 1988 to 2005.
It should be emphasized, however, that in the country as a whole,
AEDs used in other indications, as in psychiatry, are also included.
Levetiracetam was only the ninth most commonly used AED in
2006.3 Earlier studies have demonstrated that levetiracetam could
lead to seizure aggravation, both in adults and children, but
following recommendations to use a lower initial dose and a
slower dose escalation, these reactions have been avoided, and
levetiracetam has proved to be an important contribution to the
epilepsy treatment armamentarium.4,5
An interesting ﬁnding in our study was that levetiracetam
predominantly was used in epilepsies without information of
partial or generalized seizures (G40.8). This group includes
children with sleep-induced epilepsy (the majority), and a small
group of children with epilepsy syndromes such as LKS and
epilepsy with CSWS. At our centre children with 30–90%
epileptiform activity during slow wave sleep are classiﬁed within
G40.8. These nocturnal interictal discharges not classiﬁed as CSWS
are tentatively treated with levetiracetam at our centre. There are
some reports concluding that children may beneﬁt clinically from
treatment of these interictal discharges.6,7
An earlier study, also including adults, has shown that newer
AEDs are more frequently used at the centre than in the country as
a whole.8 Several studies have demonstrated that the new drugs
are equally effective, have less side effects and a lower potential for
interactions.9–11 All of these qualities are important regarding
treatment of children with severe epilepsy. The three mostfrequently used AEDs in our study, levetiracetam, valproate and
lamotrigine, all have broad spectrum effects suitable in both focal
and generalized epilepsies, used as monotherapy or as add-on. In
addition, many of the AEDs have been investigated for the use in
other CNS-related disorders that may occur as comorbid condi-
tions, which should be taken into account when considering the
optimal drug of choice for the individual patient.12
4.1.2. Age
The present study demonstrates that new AEDs were chosen
more frequently than older drugs in all age groups except in the
youngest children, and the group with unspeciﬁed epilepsies,
which included many of the youngest children. This is probably
due to the fact that the oldest children have already tried the old
drugs without a satisfying result before admission, while the
youngest have not yet reached to do so. Policy at our centre is still
in most cases to try the old AEDs ﬁrst. The use of valproate and
benzodiazepines among the youngest children probably reﬂects
their severe epilepsies with generalized/multifocal seizures, along
with the somewhat conservative approach to old vs. new AEDs at
the centre. Topiramate though, has been shown to be the drug of
choice in refractory infantile spasms (West syndrome) when
conventional drugs like adrenocorticotropic hormone (ACTH),
vigabatrin and valproate failed before admission to the centre.13
4.1.3. TDM
TDM is implemented as a part of the comprehensive care
approach to the treatment. Most often the serum concentrations of
AEDswere low in the children, but within the reference ranges and
dosage adjustments were made according to the measurements of
serum concentrations and clinical efﬁcacy. TDM is important for
several reasons; to optimize the therapy with AEDs in the
individual patient, ensure compliance of the patient/parents and
to help sorting out possible side effects and interactions both for
old and new AEDs.14–16 Measurement of serum drug concentra-
tions is especially important at the extremes of age, in this case in
children with rapid changes in physiological and pharmacokinetic
properties, to individualize the pharmacological therapy.17
4.1.4. Polytherapy
The majority of the children were using one or two AEDs, both
at admission and at discharge. Some of the children were
discharged with more AEDs than at admission. This may be due
to ongoing drug adjustments; one drug is being tapered off and the
new one is already introduced. Earlier studies at the centre have
demonstrated that polytherapy is more common in adults than in
children.8 Paediatricians are perhaps especially concerned about
polytherapy, as adverse effects may interfere with the children’s
quality of life. Some children may have a better life although still
having some seizures. During polytherapy, it is important to focus
upon the risk of pharmacokinetic interactions, as the most
frequently used AEDs are susceptible for enzyme induction or
inhibition.18 In addition, a commonly used combination in adults,
valproate and lamotrigine, has proven to give a synergistic
pharmacodynamic effect.19
4.2. Comorbidity, seizure control and everyday life
Most patients with generalized/multifocal seizure types
suffered from comorbid conditions, as did many of the children
within the three other epilepsy categories. The high prevalence of
comorbid conditionswas accompanied by one-third of the patients
being treated pharmacologically with other drugs, which in both
directions may interact and affect their medical treatment.20 Høie
et al.21 found that severe non-verbal problems were highly over-
represented in children with epilepsy, and that these deﬁcits may
E. Rytter et al. / Seizure 18 (2009) 573–579578be especially common in complex and therapy resistant epilepsies.
They concluded that their ﬁndings could be useful for the follow-
up team in developing therapy strategies to meet the individual
needs of the child with epilepsy. This underlines the need for a
comprehensive care approach to the individual child admitted
to a referral centre like ours, and supports the integrated
multidisciplinary services offered to our patients. The compre-
hensive care approach seems to beneﬁt the patients; according to
the parents, many of the children proﬁted from the stay.
Schachter22 points out that the quality of life for patients with
epilepsy is determined bymany other aspects than seizure control,
such as psychosocial factors, comorbidity and stigma. The parents’
opinions about a better everyday life take these considerations into
account. The use of AEDs, which include the practical handling of
the medication and compliance was unchanged in most cases, but
this may be due to the fact that the parents have had children with
epilepsy for several years and are well educated regarding the
treatment of their children and the importance of good com-
pliance.1 Asmost of the children referred to the centre are difﬁcult-
to-treat patients, manywith comorbid conditions, these results are
encouraging. Epilepsy is a complex medical disorder, and the
treatment should addressmany aspects. Studies have shown that a
number of recommendations of care for epilepsy are not being
met.23,24 The aim should be to eliminate or reduce both the
medical and the social consequences of the disease.
4.3. Limitations of the study
Themean duration of a stay at the centre is short (8.4 days). This
is partly due to the establishment of a short-stayward. At thisward
the children are mostly admitted for long-term video-EEG and
possible optimalization of AED-treatment, and they are regularly
re-admitted to the centre after three or four months for evaluation
of their epilepsy. Even patients at the three other wards are
regularly re-admitted to the centre, because of their difﬁcult-to-
treat epilepsy.
Another reason for the short-stays at our centre is that all
children are admitted with at least one parent. The parents are
fully compensated for their loss of income, but nevertheless they
prefer minimum absence from their work. It is also considered to
be best for the children to be as short as possible away from their
everyday life.
During a stay at the centre the withdrawal of a drug and the
introduction of another may be initiated. Optimal doses and serum
concentrations could not be identiﬁed for all patients, but the
extent of dosage adjustments was rather focused upon in
the study. The alterations will be carried through at home. The
frequent re-admissions, or alternatively an appropriate follow-up
by paediatricians/neurologists at home, still allow treatment of
high quality.
The results of this study are nation-bound, and referral
patterns may vary among Northern-Western countries. The part
of the study evaluating the impact of a stay at a referral centre,
implies several limitations: forty percent of the questionnaires
were not returned. Common features of the 104 children whose
parents did not reply were more polytherapy compared to the
children of the replying parents. This may have led to a bias of the
results. Those who returned the questionnaire may have been
more content with the stay than those who did not. But as there
are nodifferences as towhichAEDs the childrenwere using andno
differences in comorbidity, it is probably not decisive for the study
results.
Regarding the three months follow-up time, the aim was to
evaluate the status of the children after a quite short period of time
after their last stay, but at the same time, a sufﬁcient period to be
able to notice differences in adverse events and weekly/dailyseizures. Children in rapid development need close follow-up, and
a longer periodwas regarded to be too long to relate the results of a
stay at the centre to the situation of the children. Since the policy at
the centre is to offer frequent stays to the patients rather than one
prolonged stay, there will be a continuous follow-up to avoid that
the children will revert to previous seizure situation.
In conclusion, the present study demonstrates that at the
referral centre for epilepsy new AEDs were used more frequently
than older drugs in all age groups except the youngest children and
in all seizure types except unspeciﬁed epilepsies. The study
elucidates the impact of close follow-up of the children for
optimalized treatment, as conﬁrmed by the parents three months
after the stay.
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